<DOC>
	<DOCNO>NCT02388035</DOCNO>
	<brief_summary>Spontaneous bacterial peritonitis ( SBP ) serious complication cirrhotic patient , change microbiological characteristic report last year impact choice antibiotic use treatment . Cefotaxime extensively study antibiotic infection . It consider one first choice antibiotic low toxicity excellent efficacy . Treatment SBP intravenous cefotaxime administer minimum 5 day . Antibiotic-resistant microorganism increasingly report especially cefotaxime effect clinical outcome treat SBP .</brief_summary>
	<brief_title>Cefotaxime Resistance Treatment Spontaneous Bacterial Peritonitis</brief_title>
	<detailed_description />
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Cefotaxime</mesh_term>
	<mesh_term>Cefoxitin</mesh_term>
	<criteria>patient liver cirrhosis ascites clinical finding suspicious ascitic fluid infection Patients exclude receive antibiotic ten day prior hospital admission evidence secondary bacterial peritonitis , tuberculous peritonitis , malignant ascites ascites due cause e.g . cardiac renal disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>profile change</keyword>
	<keyword>microorganism</keyword>
	<keyword>cefotaxime</keyword>
	<keyword>SBP</keyword>
	<keyword>Egyptian</keyword>
	<keyword>effective antibiotic</keyword>
</DOC>